tetano
Editor, Senior Moderator
Int Immunopharmacol
. 2020 Nov 27;90:107228.
doi: 10.1016/j.intimp.2020.107228. Online ahead of print.
Therapeutic drugs for SARS-CoV-2 treatment: Current state and perspective
Joshua Adedeji Bolarin[SUP] 1 [/SUP], Mercy Adaramodu Oluwatoyosi[SUP] 2 [/SUP], Joshua Iseoluwa Orege[SUP] 1 [/SUP], Emmanuel Ayodeji Ayeni[SUP] 3 [/SUP], Yusuf Ajibola Ibrahim[SUP] 4 [/SUP], Sherif Babatunde Adeyemi[SUP] 5 [/SUP], Bashir Bolaji Tiamiyu[SUP] 6 [/SUP], Lanre Anthony Gbadegesin[SUP] 7 [/SUP], Toluwanimi Oluwadara Akinyemi[SUP] 8 [/SUP], Chuks Kenneth Odoh[SUP] 1 [/SUP], Happiness Ijeoma Umeobi[SUP] 9 [/SUP], Adenike Bernice-Eloise Adeoye[SUP] 10 [/SUP]
Affiliations
Abstract
The disease caused by viral pneumonia called severe acute respiratory syndrome coronavirus type-2 (SARS-CoV-2) declared by the World Health Organization is a global pandemic that the world has witnessed since the last Ebola epidemic, SARS and MERS viruses. Many chemical compounds with antiviral activity are currently undergoing clinical investigation in order to find treatments for SARS-CoV-2 infected patients. On-going drug-drug interaction examinations on new, existing, and repurposed antiviral drugs are yet to provide adequate safety, toxicological, and effective monitoring protocols. This review presents an overview of direct and indirect antiviral drugs, antibiotics, and immune-stimulants used in the management of SARS-CoV-2. It also seeks to outline the recent development of drugs with anti-coronavirus effects; their mono and combination therapy in managing the disease vis-?-vis their biological sources and chemistry. Co-administration of these drugs and their interactions were discussed to provide significant insight into how adequate monitoring of patients towards effective health management could be achieved.
Keywords: Antiviral drugs; COVID-19; Drug interaction; Health and safety; Therapeutics.
. 2020 Nov 27;90:107228.
doi: 10.1016/j.intimp.2020.107228. Online ahead of print.
Therapeutic drugs for SARS-CoV-2 treatment: Current state and perspective
Joshua Adedeji Bolarin[SUP] 1 [/SUP], Mercy Adaramodu Oluwatoyosi[SUP] 2 [/SUP], Joshua Iseoluwa Orege[SUP] 1 [/SUP], Emmanuel Ayodeji Ayeni[SUP] 3 [/SUP], Yusuf Ajibola Ibrahim[SUP] 4 [/SUP], Sherif Babatunde Adeyemi[SUP] 5 [/SUP], Bashir Bolaji Tiamiyu[SUP] 6 [/SUP], Lanre Anthony Gbadegesin[SUP] 7 [/SUP], Toluwanimi Oluwadara Akinyemi[SUP] 8 [/SUP], Chuks Kenneth Odoh[SUP] 1 [/SUP], Happiness Ijeoma Umeobi[SUP] 9 [/SUP], Adenike Bernice-Eloise Adeoye[SUP] 10 [/SUP]
Affiliations
- PMID: 33302035
- PMCID: PMC7691844
- DOI: 10.1016/j.intimp.2020.107228
Abstract
The disease caused by viral pneumonia called severe acute respiratory syndrome coronavirus type-2 (SARS-CoV-2) declared by the World Health Organization is a global pandemic that the world has witnessed since the last Ebola epidemic, SARS and MERS viruses. Many chemical compounds with antiviral activity are currently undergoing clinical investigation in order to find treatments for SARS-CoV-2 infected patients. On-going drug-drug interaction examinations on new, existing, and repurposed antiviral drugs are yet to provide adequate safety, toxicological, and effective monitoring protocols. This review presents an overview of direct and indirect antiviral drugs, antibiotics, and immune-stimulants used in the management of SARS-CoV-2. It also seeks to outline the recent development of drugs with anti-coronavirus effects; their mono and combination therapy in managing the disease vis-?-vis their biological sources and chemistry. Co-administration of these drugs and their interactions were discussed to provide significant insight into how adequate monitoring of patients towards effective health management could be achieved.
Keywords: Antiviral drugs; COVID-19; Drug interaction; Health and safety; Therapeutics.